Scholarlink

<p>Investigating the association between metabolic syndrome (MetS) and all its components with prediagnostic Parkinson’s disease (PD) may clarify PD pathogenesis and identify candidates for prevention strategies and neuroprotective trials. We conducted a retrospective study of 890 PD patients diagnosed during 2000-2020 and 8,100 matched controls, analyzing electronic health records up to 15 years before PD diagnosis. Prevalence was assessed annually to track changes in association strength over time. PD patients consistently showed lower MetS prevalence (OR = 0.57–0.8). Compared to controls, PD patients had lower triglycerides (OR = 0.44–0.75), BMI (OR = 0.54–0.65), and hyperglycemia (OR = 0.81–0.86) rates, and females showed higher high-density lipoprotein (HDL) (OR = 1.48–1.82), lower low-density lipoprotein/HDL ratio (OR = 0.46–0.64), and reduced hypertension (OR = 0.79–0.85). These findings suggest an inverse association between MetS and PD years before diagnosis. We propose a lipid–blood pressure index incorporating triglycerides, HDL, and hypertension as a potential clinical tool for PD risk stratification.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Lower prevalence of metabolic syndrome and its components in the prediagnostic phase of Parkinson’s disease

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月4日

查看全文
  • Hila Avisar,
  • Uri Greenbaum,
  • Ruth Djaldetti,
  • Boaz Lerner

摘要

Investigating the association between metabolic syndrome (MetS) and all its components with prediagnostic Parkinson’s disease (PD) may clarify PD pathogenesis and identify candidates for prevention strategies and neuroprotective trials. We conducted a retrospective study of 890 PD patients diagnosed during 2000-2020 and 8,100 matched controls, analyzing electronic health records up to 15 years before PD diagnosis. Prevalence was assessed annually to track changes in association strength over time. PD patients consistently showed lower MetS prevalence (OR = 0.57–0.8). Compared to controls, PD patients had lower triglycerides (OR = 0.44–0.75), BMI (OR = 0.54–0.65), and hyperglycemia (OR = 0.81–0.86) rates, and females showed higher high-density lipoprotein (HDL) (OR = 1.48–1.82), lower low-density lipoprotein/HDL ratio (OR = 0.46–0.64), and reduced hypertension (OR = 0.79–0.85). These findings suggest an inverse association between MetS and PD years before diagnosis. We propose a lipid–blood pressure index incorporating triglycerides, HDL, and hypertension as a potential clinical tool for PD risk stratification.